Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mindi DePaola"'
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195012 (2018)
For nearly a century, no generic form of insulin has been available in the United States. However, the first biosimilar insulin, Basaglar, was approved by the U.S. Food and Drug Administration in 2015, and subsequently Admelog and Lusduna in 2017.To
Externí odkaz:
https://doaj.org/article/29fcfdec75334fcea4de1953ab26c53b
Autor:
Ananya Roy, Henry Roman, William Raich, Maria Harris, Mindi DePaola, Taylor Bacon, Stefani Penn, Joseph Chang, Melanie Jackson
Publikováno v:
ISEE Conference Abstracts. 2022
Autor:
Sarah Robbins-Scott, Ellen Dugan, Jonathan Schmelzer, Kathryn Razavi-Shearer, Mia J. Biondi, Sarah Blach, Poonam Mathur, Chris Estes, Siya Ma, Zongzhen Cai, Devin Razavi-Shearer, Homie Razavi, Shauna Montoya, Shyamasundaran Kottilil, Ivane Gamkrelidze, Jordan J. Feld, Mindi DePaola
Publikováno v:
The Lancet Gastroenterology & Hepatology. 6:169-184
Summary Background Treatment for infection with hepatitis C virus (HCV) during pregnancy has not yet been approved; however, interventions specifically targeting women, especially those of childbearing age (15–49 years), could prevent vertical tran
Autor:
Samantha Coleman, Sarah Blach, Zongzhen Cai, Devin Razavi-Shearer, Kathryn Razavi-Shearer, Siyi Ma, Shauna Montoya, Chris Estes, Kathryn Jerabek, Homie Razavi, Manal Hamdy El Sayed, Ivane Gamkrelidze, Jonathan Schmelzer, Mindi DePaola, Sarah Robbins-Scott, Ellen Dugan
Publikováno v:
The Lancet Gastroenterology & Hepatology. 5:374-392
Hepatitis C virus (HCV) prevalence estimates for adults and high-risk groups have been widely published, but the disease burden in children is poorly understood. Direct-acting antiviral drugs, which are considered to be highly effective curative ther
Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 4, p e0195012 (2018)
PLoS ONE, Vol 13, Iss 4, p e0195012 (2018)
Importance For nearly a century, no generic form of insulin has been available in the United States. However, the first biosimilar insulin, Basaglar, was approved by the U.S. Food and Drug Administration in 2015, and subsequently Admelog and Lusduna